Residual Risk–Based Eligibility in Breast Cancer Adjuvant Trials

This modeling study calculates individualized residual risk estimates for patients with early-stage breast cancer and assesses whether defining eligibility based on a minimum residual risk threshold could increase the reliability of clinical trial power calculations.

from Cancer via ola Kala on Inoreader https://ift.tt/2DCCSUN
via IFTTT